Hila Magen

Spécialisation: Hematologist
35 années d'expérience
Parle:
English, Hebrew
Consultations en ligne : disponibles
Espace de travail: Israël, Ramat Gan, Centre médical Sheba
Heads a Multiple Myeloma & Amyloidosis unit; 100+ scientific publications; principal investigator for point-of-care CAR-T programs.
Dr. Hila Magen is a leading Israeli hemato-oncologist at Sheba Medical Center. She heads the Multiple Myeloma and Amyloidosis Unit. Dr. Magen specializes in treating complex plasma cell disorders and high-risk myeloma. She is a principal investigator for innovative point-of-care CAR-T therapy programs. Her work brings advanced immunotherapies into routine clinical care.
- Authored over 100 scientific publications and landmark myeloma studies.
- Completed fellowships at MD Anderson and University of Arkansas for Medical Sciences.
- Performs CAR-T cell therapy and bone marrow transplantations.
- Works at Sheba Medical Center, ranked 7th worldwide in 2026 by Newsweek.

Consultation en ligne avec Hila Magen

Pratique et facile

100 % sécurisé et confidentiel

$650

Services du médecin

Où en sommes-nous ?

1 de 3

Les détails sur ce médecin sont exhaustifs et clairs

Fortement en désaccord

Fortement d’accord

Qualifications

Dr. Hila Magen directs the Multiple Myeloma and Amyloidosis Unit at Sheba Medical Center. She is an expert in plasma cell disorders and advanced cellular therapies. The specialist is a principal investigator for point-of-care CAR-T cell programs.

Specialization in Plasma Cell Disorders

Dr. Magen treats relapsed and refractory multiple myeloma. She treats amyloidosis and various plasma cell malignancies using precision medicine. The specialist integrates new immunotherapies into routine clinical care for high-risk patients. Her approach involves creating targeted treatment plans to improve long-term survival.

Advanced Cellular Therapies and Procedures

The doctor applies CAR-T cell therapy for blood cancers. She offers patients early access to treatments through international clinical trials. Dr. Magen performs or oversees several critical hematologic procedures:

CAR T-cell therapy — a treatment that uses genetically modified immune cells to attack cancer
Bone marrow transplantation from related and unrelated donors
Haploidentical stem cell transplantation
Therapeutic apheresis and plasmapheresis — procedures that filter and clean a patient's blood
Diagnostic bone marrow biopsy and immunohistochemistry

Work Experience and Leadership

Head of the Multiple Myeloma and Amyloidosis Unit at Sheba Medical Center
Instructor at Tel Aviv University
Principal Investigator for point-of-care CAR-T cell research studies
Active reviewer for several international medical journals

Education and International Training

Fellowship in Multiple Myeloma – University of Arkansas for Medical Sciences (UAMS)
Fellowship in Lymphocytic Leukemia – MD Anderson Cancer Center, USA
MD Degree in General Medicine

Research and Academic Achievements

Dr. Magen has authored over 100 scientific publications in peer-reviewed journals. She has contributed to multiple landmark studies regarding myeloma treatment protocols. The doctor frequently presents her clinical findings at international hematology conferences. She focuses her research on developing next-generation cellular therapies for refractory diseases.

Professional Memberships

The doctor is a member of several professional organizations:

European Hematology Association (EHA)
American Society of Hematology (ASH)
Israel Society of Hematology and Blood Transfusion